Newer Tools in Drug Discovery

1. High-Throughput Screening (HTS)

• Advantages: Unbiased exploration of chemical space; can identify novel scaffolds
• Limitation: Generates many false positives; active compounds may have poor drug-like properties (e.g., nonspecific binding)

2. Fragment-Based Drug Discovery (FBDD)

• Detection methods: X-ray crystallography, NMR, surface plasmon resonance (SPR)
• Advantages: Higher hit rates due to simpler chemical space; yields efficient ligands with good selectivity
• Key example: Venetoclax (BCL-2 inhibitor for CLL) was discovered via FBDD

"Fragment-Based Drug Discovery" — Goodman & Gilman's, block1.md

3. Computer-Aided Drug Discovery (CADD)

a. Structure-Based Drug Design (SBDD)

• Tools: Autodock, Glide, Schrödinger Suite
• Requires high-resolution structural data (now significantly boosted by cryo-EM)

b. Ligand-Based Drug Design (LBDD) / Chemical Similarity

• Uses pharmacophore modeling, fingerprint similarity searches
• Searches large databases (e.g., ZINC, ChemBL) for analogs of known actives

"COMPUTER-AIDED DRUG DISCOVERY / Using Chemical Similarity to Discover Targeted Ligands" — Goodman & Gilman's, block1.md

4. Artificial Intelligence (AI) & Machine Learning (ML)

Key Applications:

AlphaFold2

Generative AI

"Artificial Intelligence in Drug Discovery" — Goodman & Gilman's, block1.md
Gangwal A & Lavecchia A. Unleashing the power of generative AI in drug discovery. Drug Discov Today, 2024. [PMID: 38663579]

5. Phenotypic Screening

• Can identify drugs with novel or multi-target mechanisms
• Avoids the risk of selecting a well-validated-but-irrelevant target
• Has been rehabilitated in the past decade after target-based approaches yielded lower-than-expected success rates

6. DNA-Encoded Chemical Libraries (DEL)

• Enables screening of 10⁸–10¹² compounds in a single experiment
• Used extensively in pharma (AstraZeneca, GSK)

7. Cryo-Electron Microscopy (Cryo-EM)

• Large complexes (GPCRs, ion channels, ribosomes)
• Membrane proteins historically refractory to X-ray crystallography
• Proteins in multiple conformational states

8. PROTAC Technology (Targeted Protein Degradation)

1. Bind the target protein
2. Recruit an E3 ubiquitin ligase
3. Induce ubiquitination and proteasomal degradation of the target

• Advantages: Can degrade "undruggable" proteins; catalytic mechanism (sub-stoichiometric drug doses possible)
• In clinical trials for cancers (e.g., ARV-110 for prostate cancer)

9. CRISPR-Based Target Validation

10. Organ-on-a-Chip / Microphysiological Systems

Summary Table

• Goodman & Gilman's The Pharmacological Basis of Therapeutics — Chapter 1, Drug Discovery sections
• Katzung's Basic and Clinical Pharmacology, 16th Edition — Drug Discovery chapter
• Gangwal A & Lavecchia A. Unleashing the power of generative AI in drug discovery. Drug Discov Today. 2024. [PMID: 38663579]
• Vora LK et al. AI in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics. 2023. [PMID: 37514102]

The Revolutionary Tools in Drug Discovery — PubMed Evidence (2023–2026)

🏆 #1 Revolution: Artificial Intelligence & AlphaFold

AlphaFold (2/3): The Nobel-Prize-Winning Paradigm Shift

"The AlphaFold initiative profoundly impacted structural biology, evidenced by its 2024 Nobel Prize. AlphaFold progressed from AF1 to AF2 (near-experimental accuracy in protein folding) to AF3, expanding predictions to protein-ligand, protein-nucleic acid, and protein-protein complexes." — Chakraborty C et al., Front Artif Intell, 2026 [PMID: 42027778]

• Before AlphaFold, structural determination required years of X-ray crystallography or NMR
• The AlphaFold Database (AFDB) now contains predicted structures for >200 million proteins — virtually all known proteins
• Directly enabled structure-based drug design (SBDD) for previously "undruggable" targets

AI Platforms — 2025 Landscape

"AI-designed therapeutics are now in human trials across diverse therapeutic areas... Key developments since 2024 include positive Phase IIa results for Insilico Medicine's ISM001-055 in idiopathic pulmonary fibrosis; advancement of zasocitinib (TAK-279) into Phase III exemplifies Schrödinger's physics-enabled design strategy reaching late-stage clinical testing." — Dharmasivam M et al., Pharmacol Rev, 2026 [PMID: 41389441]

• 🔬 Insilico Medicine → AI-designed ISM001-055 (IPF kinase inhibitor) → Phase IIa positive results (2024)
• 💊 BenevolentAI → Identified baricitinib for COVID-19 treatment (later FDA-authorized)
• 🧪 Schrödinger/Nimbus → Zasocitinib (TAK-279), a TYK2 inhibitor for psoriasis → Phase III trials
• 🤝 Recursion + Exscientia merger → Full end-to-end phenomics + AI chemistry platform

"AI tools such as AlphaFold for protein structure prediction and AtomNet for structure-based drug design have significantly accelerated the discovery process, improved efficiency, and reduced costs." — Jarallah SJ et al., Int J Pharm, 2025 [PMID: 40451590]

Self-Driving Laboratories

🏆 #2 Revolution: PROTACs (Targeted Protein Degradation)

"PROTACs represent a transformative advancement in drug discovery, offering a method to degrade specific intracellular proteins... enabling treatment of previously 'undruggable' proteins." — Berkley K et al., Biochemistry, 2025 [PMID: 39791901]

• Multiple PROTACs in Phase I/II trials for cancers (AR degraders for prostate cancer, BRD4 degraders)
• Neurodegenerative disease applications (tau, alpha-synuclein degradation) in development
• Novel subtypes: Fluorescent PROTACs for real-time tracking of protein degradation in cells [PMID: 39791901]

🏆 #3: CRISPR in Drug Discovery

"CRISPR-based therapies are revolutionizing drug development and precision medicine." — Chanchal DK et al., Curr Gene Ther, 2024 [PMID: 38310456]

1. Target identification & validation — Genome-wide CRISPR knockout screens identify which genes are essential in disease (e.g., which cancer genes are synthetic lethal)
2. Direct therapeutics — CRISPR-Cas9 as a drug itself (e.g., Casgevy for sickle cell disease — first CRISPR medicine approved by FDA/EMA in 2023)

Evidence-Based Ranking: Which Is the Biggest Revolution?

Key PubMed References

🧬 AlphaFold 3: In-Depth Seminar Presentation

SLIDE 1 — Title & Overview

"High-accuracy modelling across biomolecular space is possible within a single unified deep-learning framework." — Abramson J et al., Nature, 2024 [PMID: 38718835]

SLIDE 2 — The Problem AlphaFold Solves

The Protein Folding Problem (50-Year-Old Challenge)

• Every protein is a linear chain of amino acids that folds into a 3D shape in milliseconds
• The 3D shape determines the protein's function — and whether a drug can bind it
• Determining structure experimentally (X-ray crystallography, cryo-EM, NMR) takes months to years per protein and costs hundreds of thousands of dollars
• The human genome encodes ~20,000 proteins; as of 2020, only ~170,000 structures were known across all species

Why it matters for drug discovery:

No structure → No rational drug design

SLIDE 3 — Evolution: AF1 → AF2 → AF3

"AF1 uses deep neural networks, AF2 employs the Evoformer to model evolutionarily related sequences, and AF3 applies the Pairformer for pairwise amino acid interactions." — Chakraborty C et al., Front Artif Intell, 2026 [PMID: 42027778]

SLIDE 4 — AlphaFold 3 Architecture (Core Mechanics)

Three-Part Framework:

INPUT MODULE
    ↓
ENCODER (Pairformer)
    ↓
DIFFUSION MODULE → 3D Structure Output

1. Input Module

• Collects Multiple Sequence Alignments (MSAs) and template structures
• MSA simplified to just 4 sequences (vs. hundreds in AF2) → massively reduced computational cost
• Handles ALL molecular types simultaneously: proteins, DNA, RNA, ligands, ions, modified residues

2. Pairformer (replaces Evoformer of AF2)

• Core encoder using an improved transformer architecture
• Retains triangular update and triangular self-attention from AF2's Evoformer
• Focuses on pairwise amino acid interactions (decouples MSA from pair processing)
• Captures spatial relationships via residue-pair representations
• Stacked 48 layers — same depth as AF2's Evoformer but architecturally cleaner

3. Diffusion Module (the key innovation)

• Borrowed from image generation AI (like DALL-E / Stable Diffusion)
• Starts with random atomic noise and iteratively refines it into a precise 3D structure
• Operates directly at the all-atom level — predicts exact positions of every atom
• Enables prediction of flexible molecules (small drug-like ligands) not possible in AF2
• Generates multiple plausible conformations (stochastic sampling)

From PMC review: "By introducing an innovative diffusion model architecture, AF3 has powerfully improved prediction accuracy. This leapfrog development enables algorithm-driven structural prediction to no longer be limited to a single molecular type." [PMC12342994]

SLIDE 5 — What's New: AF2 vs AF3 Head-to-Head

SLIDE 6 — Performance Benchmarks

FoldBench (2025) — Largest Comprehensive Benchmark

"AlphaFold 3 consistently demonstrates superior accuracy across the majority of tasks." — Xu S et al., Nat Commun, 2025 [PMID: 41345395]

• Ligand docking accuracy diminishes as ligand similarity to training set decreases (generalization gap)
• Antibody–antigen predictions remain challenging — failure rates exceeding 50% (current bottleneck)
• Best-in-class for protein–protein, protein–DNA, protein–RNA, and protein–ligand tasks

Monomeric Protein Accuracy (PDB 2022–2024)

• AlphaFold 2 and AlphaFold 3: comparable for monomers — both ~87–88% accuracy
• ESMFold: 77%
• For X-ray / cryo-EM structures specifically: AF accuracy rises to 95%
• Key limitation: AF2 and AF3 both struggle with NMR-derived structures (67–71% failure) due to conformational variability

PoseBusters Benchmark (Protein–Ligand Docking)

• AF3: ~76% success rate on PoseBusters
• Chai-1 (open-source AF3 descendant): ~77–81% (comparable)
• Traditional docking tools (AutoDock, Glide): substantially lower

SLIDE 7 — Applications in Drug Discovery

1. Structure-Based Drug Design (SBDD) — Supercharged

• Enables rational design of molecules that fit the target's binding pocket
• Expanded scope to membrane proteins, GPCRs, ion channels — previously "undruggable" due to crystallization difficulty

2. Real Drug Discovery Example: MRGPRX2 Antagonists (2026)

1. Predict the 3D structure of MRGPRX2 (a mast cell receptor with no available crystal structure in inhibitory conformation)
2. Perform virtual screening of 23,562 compounds using Schrödinger software
3. Identify top 30 candidates → validated in cell assays → identified HCH6-1 as novel antagonist
4. In vivo: HCH6-1 showed therapeutic effect in MRGPRX2-related atopic dermatitis

"Our research demonstrated the use of AlphaFold 3 for protein structure prediction and virtual screening and discovered a novel small molecule MRGPRX2 antagonist." — Zhang Y et al., Biochem Pharmacol, 2026 [PMID: 41138926]

3. PROTAC & Molecular Glue Design

• Both models outperformed all prior approaches in accuracy AND runtime
• AF3 showed good accuracy for VHL-based PROTACs and molecular glues
• Failures mainly in flexible, twisting ternary complexes

— Riepenhausen L et al., Arch Pharm, 2026 [PMID: 41831109]

4. Antibody Engineering

• Predicts antibody–antigen complexes — critical for biologics development
• Accelerates CDR loop design and epitope mapping
• Used in vaccine design for viral antigens (COVID-19, influenza)

5. Nucleic Acid Drug Design

• Predicts RNA/DNA secondary and tertiary structures
• Enables design of antisense oligonucleotides, siRNAs, aptamers
• Key for targeting RNA viruses and non-coding RNA disease mechanisms

SLIDE 8 — AlphaFold Database (AFDB)

SLIDE 9 — The Post-AlphaFold Ecosystem (2024–2026)

SLIDE 10 — Limitations & Open Challenges

Known Limitations:

"The protein structure predicted by AF3 provides site information but cannot simulate the conformational dynamic changes triggered by energy changes, restricting application in drug dynamic interactions." [PMC12342994]

SLIDE 11 — Integration with Other Drug Discovery Tools

AlphaFold 3 Structure
        ↓
  Virtual Screening (Schrödinger, AutoDock)
        ↓
  Molecular Dynamics (GROMACS, AMBER) ← fills AF3 dynamic gap
        ↓
  Free Energy Perturbation (FEP+)
        ↓
  ADMET Prediction (AI tools)
        ↓
  Clinical Candidate

SLIDE 12 — Nobel Prize 2024 Context

• David Baker (University of Washington) — for computational protein design
• Demis Hassabis & John Jumper (Google DeepMind) — for AlphaFold

SLIDE 13 — Summary: Why AlphaFold 3 is a Revolution

SLIDE 14 — Key References for Seminar

Seminar Talking Points (Highlight for Q&A)

1. "Why is the diffusion module the key innovation?" → It allows generation of all-atom 3D coordinates for any molecule type (not just standard amino acids), and can generate multiple conformations — unlike AF2's deterministic output.
2. "Is AF3 open-source?" → Partially. The code is available on GitHub but the model weights for the full system are restricted. Multiple teams (OpenFold, Boltz, Chai) are rebuilding open-source equivalents.
3. "Does AF3 replace crystallography?" → No. Crystallography/cryo-EM remain gold standards, especially for dynamic structures and drug-bound states. AF3 complements experiments by predicting starting structures, guiding where to look, and filling gaps where crystals fail.
4. "What is the biggest remaining gap?" → Dynamics and energetics. AF3 gives a static snapshot; it cannot tell you how a protein moves, what the binding free energy is, or how a drug changes protein behavior over time.
5. "What is the most exciting near-future application?" → Isomorphic Labs (DeepMind spinout, 2023) is using AF3-level models as the core of an end-to-end drug design engine — potentially compressing the entire preclinical phase from years to months.